Health Care • Biotechnology: Pharmaceutical Preparations
$3.58 ▼ -0.23
(-6.04%)
MKT CAP: $33.5M • VOL: 176.2K
52W L $3 52W H $12
ROARABLE / RQD
D- • 36/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$3
MEDIAN
$4
MEAN
$4
HIGH
$5
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ACET TAPE
ACET // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $4.33 | $4.12 | 2025-02-14 | $3.26 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $4.51 | $4.22 | 2025-02-06 | $3.37 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $4.08 | $3.94 | 2025-01-29 | $3.44 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $3.65 | — | 2025-01-17 | $3.51 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $3.15 | $3.40 | 2025-01-09 | $3.19 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $4.26 | $3.72 | 2024-12-18 | $3.11 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $3.47 | $3.62 | 2024-12-04 | $3.33 | -4.3% | 48% | C |